The latest price target for Biogen (NASDAQ:BIIB) was reported by Cantor Fitzgerald on September 9, 2024. The analyst firm set a price target for $292.00 expecting BIIB to rise to within 12 months (a possible 47.78% upside). 66 analyst firms have reported ratings in the last year.

The latest analyst rating for Biogen (NASDAQ:BIIB) was provided by Cantor Fitzgerald, and Biogen reiterated their overweight rating.

The last upgrade for Biogen Inc happened on December 7, 2023 when Raymond James raised their price target to $283. Raymond James previously had a market perform for Biogen Inc.

The last downgrade for Biogen Inc happened on February 14, 2024 when Wells Fargo changed their price target from $315 to $240 for Biogen Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biogen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biogen was filed on September 9, 2024 so you should expect the next rating to be made available sometime around September 9, 2025.

While ratings are subjective and will change, the latest Biogen (BIIB) rating was a reiterated with a price target of $292.00 to $292.00. The current price Biogen (BIIB) is trading at is $197.59, which is out of the analyst’s predicted range.